FinVector is a world leader in cGMP manufacturing of Viral-Based Gene Therapy products. Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an excellent reputation in the gene therapy market. We are authorised under EMA for the production of gene therapy products for clinical and commercial supply. We offer services across a wide range of viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors. From our cutting-edge fully-licensed GMP manufacturing facility in Finland, we have built an extensive pipeline of gene therapy products and technologies for our clients. Find out more about our services by visiting our webpage. Our mission is to improve and extend people's lives by finding solutions in advanced medicines. Moreover, we want to be a company that people aspire to work for. FinVector is a lively and international working community with a wide range of career opportunities. We currently employ over 300 employees from 30 different countries.